LRMR
Larimar Therapeutics, Inc.NASDAQHealthcare$4.79+5.43%ClosedMarket Cap: $409.9M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.51
P/S
0.00
EV/EBITDA
-2.06
DCF Value
$1.06
FCF Yield
-26.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-137.7%
ROA
-113.6%
ROIC
-210.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-64.0M | $-62.5M | $-0.73 | — |
| FY 2025 | $0.00 | -Infinity% | $-172.5M | $-165.7M | $-2.27 | — |
| Q3 2025 | $0.00 | NaN% | $-49.5M | $-47.7M | $-0.61 | — |
| Q2 2025 | $0.00 | NaN% | $-27.8M | $-26.2M | $-0.41 | — |
| Q1 2025 | $0.00 | NaN% | $-31.2M | $-29.3M | $-0.46 | — |
| Q4 2024 | $0.00 | NaN% | $-31.3M | $-28.8M | $-0.45 | — |
| FY 2024 | $0.00 | NaN% | $-90.9M | $-80.6M | $-1.32 | — |
| Q3 2024 | $0.00 | NaN% | $-18.3M | $-15.5M | $-0.24 | — |
| Q2 2024 | $0.00 | NaN% | $-24.6M | $-21.6M | $-0.34 | — |
| Q1 2024 | $0.00 | -Infinity% | $-16.7M | $-14.7M | $-0.27 | — |
| Q4 2023 | $0.00 | -Infinity% | $-14.2M | $-13.0M | $-0.30 | — |
| FY 2023 | $0.00 | NaN% | $-41.8M | $-36.9M | $-0.84 | — |